Changing the finish line: Syneos talks bringing payer, patient voice into drug development

By Melissa Fassbender contact

- Last updated on GMT

The drug development “finish line” is not regulatory approval, says Syenos Health chief scientific officer Judith Ng-Cashin, MD, who discusses bringing the payer and patient voice into the process.

Outsourcing-Pharma sat down with Ng-Chasin at the Syneos Health headquarters in Raleigh, NC ahead of the DIA 2018 Global Annual Meeting, which takes place next week.

The conference is a “great space”​ for conversation and neutral safe harbor for sponsors, contract research organizations (CROs), regulators, and payers, said Ng-Chasin, who was elected to the DIA Board of Directors in 2017.

“I think that element we talk about on the [DIA] board of involving the payer voice now at DIA is really starting to evolve as a trend,”​ she told us – noting that while it is not a new trend, it continues to affect how companies develop new therapies.

“Your finish line isn’t regulatory approval – your finish line is past market authority and really about reaching the right patients and also appropriate reimbursement,”​ she explained. For these reasons, among others, Ng-Chasin said bringing the payer and patient voice into the mix is important.

“People are starting to change their thinking,”​ she added, specifically about endpoints and the definition of clinically meaningful impact.

“Sometimes it’s ‘I don’t need to walk for six minutes, I need to be able to get from my bed to the bathroom by myself’ – that’s meaningful.”

Watch the above video to hear more of Ng-Chasin’s comments on DIA and the evolving drug development industry.

Related news

Show more

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars